Skip to content
ADPT·Nasdaq·US

Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products. Its main business includes immune medicine and the clonoSEQ assay, an FDA-cleared diagnostic for minimal residual disease monitoring in blood cancers.

Recent Activity

Updated Oct 3, 2026
–Adaptive Biotechnologies highlighted the role of its highly sensitive MRD testing technology in a new International Myeloma Society definition of cure for myeloma, which requires five years off treatment with sustained MRD negativity assessed by technology sensitive enough to detect one myeloma cell among a million.
–Adaptive Biotechnologies highlighted updated National Comprehensive Cancer Network multiple myeloma guidelines.

Past updates are part of the Pro plan.

Thematic Position

ADPT

Relationship Groups

Suppliers2
Partners3
Licensing1

Relationship details are part of the Pro plan.

Ended Relationships

5 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

regulatory requirementlicensurecertification
CLIA and state laboratory regulations impose certification and licensure requirements on Adaptive
SEC 10-KFeb 26, 2026

The full regulatory passage is part of the Pro plan.

7 more · Regulatory and geopolitical insights are part of the Pro plan.